No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Cynata Therapeutics to Act as Core Partner in Australian Regenerative Therapy Manufacturing Initiative; Shares Up 3%
Cynata Therapeutics Appoints Scientific Advisory Board, Shares Down 3%
Cynata Therapeutics Reports Positive Efficacy Data From Heart Disease Treatment Candidate
Cynata Therapeutics Ltd: Appendix 4D & Half-Year Financial Statements
Cynata Therapeutics Limited (ASX:CYP): Is Breakeven Near?
US FDA Approval of Mesenchymal Stromal Cell Therapy Bodes Well for Cynata Therapeutics, Euroz Hartleys Says